Preeclampsia Diagnostics Market Size, Share, and Growth Analysis, By Test Type (Blood Tests, Urine Analysis), By Product (Instruments, Consumables), By End-user, By Region - Industry Forecast 2025-2032
자간전증 진단약 시장 규모는 2023년에 10억 9,000만 달러로 평가되며, 2024년 11억 2,000만 달러에서 2032년에는 14억 3,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 3.1%로 성장할 전망입니다.
세계 자간전증 진단제 시장은 임산부 건강에 대한 인식 증가와 임신 관련 합병증의 복잡성에 힘입어 크게 성장하고 있습니다. 심각한 고혈압성 질환인 자간전증은 산과 의료에 큰 위험을 초래하므로 정확한 조기 진단법에 대한 수요가 증가하고 있습니다. 이에 따라 주요 시장 참여자들은 조기 발견 및 조기 관리 개선을 위한 진단 기술 혁신을 추진하고 있습니다. 의료비 증가, 신흥 시장의 의료 인프라 강화, 산부인과 의료에 대한 첨단 의료 기술 도입 등의 요인이 시장 확대를 더욱 촉진하고 있습니다. 그러나 고가의 첨단 진단법 비용과 일부 지역에서는 의료 접근성이 제한적이라는 점이 문제점으로 지적되고 있습니다. 새로운 바이오마커와 비침습적 진단법에 대한 연구가 진행됨에 따라 시장은 당분간 지속적인 발전을 이룰 것으로 보입니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 상황
- 사례 연구
- 기술의 진보
자간전증 진단약 시장 규모 : 검사 유형별 & CAGR(2025-2032)
자간전증 진단약 시장 규모 : 제품별 & CAGR(2025-2032)
자간전증 진단약 시장 규모 : 최종사용자별 & CAGR(2025-2032)
자간전증 진단약 시장 규모 : 지역별 & CAGR(2025-2032)
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 기업의 상세
- 제품 포트폴리오 분석
- 기업의 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024)
주요 기업 개요
- Diabetomics Inc.(United States)
- DRG Instruments GmbH(Germany)
- F. Hoffmann-La Roche Ltd(Switzerland)
- PerkinElmer Inc.(United States)
- Siemens Healthineers AG(Germany)
- Thermo Fisher Scientific(United States)
- GE Healthcare(United States)
- Abbott Laboratories(United States)
- Acon Laboratories, Inc.(United States)
- Arkray, Inc.(Japan)
- Bio-Rad Laboratories, Inc.(United States)
- Cardinal Health(United States)
- Danaher Corporation(Beckman Coulter, Inc.)(United States)
- DIRUI Industrial Co., Ltd.(China)
- Metabolomic Diagnostics Ltd.(Ireland)
- Sera Prognostics(United States)
- Synlab Group(Germany)
- Microlife Corporation(Switzerland)
- Bayer AG(Germany)
- Progenity Inc.(United States)
결론과 제안
KSA
Preeclampsia Diagnostics Market size was valued at USD 1.09 billion in 2023 and is poised to grow from USD 1.12 billion in 2024 to USD 1.43 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).
The global preeclampsia diagnostics market is experiencing significant growth, driven by heightened awareness surrounding maternal health and the complexities of pregnancy-related complications. As preeclampsia, a serious hypertensive condition, poses substantial risks in obstetrics, the demand for precise and early diagnostic methods is escalating. Consequently, major market players are innovating diagnostic technologies aimed at improving early detection and management. Factors such as rising healthcare expenditures, enhancements in healthcare infrastructure in emerging markets, and the incorporation of advanced medical technologies in obstetric care are further propelling market expansion. However, high costs of sophisticated diagnostic methods and limited healthcare access in certain regions may pose challenges. With ongoing research into novel biomarkers and non-invasive diagnostics, the market is poised for continued advancements in the foreseeable future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Preeclampsia Diagnostics Market Segments Analysis
Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Preeclampsia Diagnostics Market
The Preeclampsia Diagnostics market is driven by the challenges associated with accurately diagnosing the condition in pregnant women. A solitary increase in blood pressure is not a definitive indicator of preeclampsia, complicating the diagnosis process. Furthermore, many expectant mothers lack awareness of preeclampsia and its associated risks, which can lead to hypertension during pregnancy going undetected until it escalates, thereby restricting timely intervention opportunities. This gap in knowledge not only poses significant health risks to the women affected but also heightens the likelihood of increased infant mortality rates, underscoring the urgent need for effective diagnostic solutions and education.
Restraints in the Preeclampsia Diagnostics Market
The preeclampsia diagnostics market faces significant challenges due to the complexities involved in diagnosing the condition in pregnant women. A mere increase in blood pressure is not a definitive indicator of preeclampsia, making accurate identification difficult. Furthermore, a considerable number of expectant mothers lack knowledge about preeclampsia, which severely limits their understanding of the associated risks. As hypertension often goes undetected until more severe symptoms arise, this oversight restricts timely intervention options. The resultant unawareness poses considerable risks to maternal health and significantly heightens infant mortality rates, emphasizing the critical need for improved awareness and diagnostic methods in this area.
Market Trends of the Preeclampsia Diagnostics Market
The global preeclampsia diagnostics market is witnessing a significant trend towards early risk assessment for pregnant women, propelling the adoption of biomarker-based tests designed for the early detection of this condition. By focusing on specific biological markers, healthcare providers can more accurately identify potential preeclampsia cases, which enables timely interventions crucial for improving maternal and fetal health outcomes. This proactive diagnostic approach aligns with the overarching goals of healthcare systems to enhance maternal care and reduce the adverse effects of preeclampsia on pregnancies. As awareness and demand for early intervention grow, the market for innovative diagnostic solutions is expected to flourish in tandem.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Case Studies
- Technological Advancement
Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2025-2032)
- Market Overview
- Blood Tests
- Urine Analysis
- Others
Global Preeclampsia Diagnostics Market Size by Product & CAGR (2025-2032)
- Market Overview
- Instruments
- Consumables
Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2025-2032)
- Market Overview
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Global Preeclampsia Diagnostics Market Size & CAGR (2025-2032)
- North America (Test Type, Product, End-user)
- Europe (Test Type, Product, End-user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Test Type, Product, End-user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Test Type, Product, End-user)
- Brazil
- Rest of Latin America
- Middle East & Africa (Test Type, Product, End-user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Diabetomics Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DRG Instruments GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acon Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arkray, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cardinal Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (Beckman Coulter, Inc.) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DIRUI Industrial Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Metabolomic Diagnostics Ltd. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sera Prognostics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Synlab Group (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Microlife Corporation (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Progenity Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
